Clinical Trial Research

Novel cholesterol uptake inhibitor ZETIA approved in Japan

Published in Healthcare Mergers, Acquisitions and Ventures Week, May 12th, 2007

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved ZETIA(R) (ezetimibe), a novel cholesterol-lowering agent that inhibits the absorption of cholesterol in the intestines. ZETIA(R) will be co-marketed by Bayer Yakuhin Ltd. and Schering-Plough K.K. Japan. The drug is approved for use either as monotherapy or co-administered with a statin, for further reduction of LDL "bad" cholesterol.

ZETIA(R), which works in the digestive tract to inhibit the absorption of cholesterol, is complementary to the class of cholesterol-lowering agents known as statins, which work in the liver to reduce the production of cholesterol. In a multi-center, randomized,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week

Source: Healthcare Mergers, Acquisitions and Ventures Week (2007-05-12)

More Articles from Healthcare Mergers, Acquisitions and Ventures Week

3D Systems Corporation
3D Systems Recruits Chief Financial Officer
AARP
Calls for Rx Marketing Reform to Lower Cost of Prescription Drugs
ABB
ABB Announces PAT Solution for the Life Sciences Industry
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Announces Exercise of Over-Allotment by Underwriters
Aceto Corporation
Aceto Schedules Third Quarter Financial Results News Release and Conference Call
Acne Vulgaris
Acne Sufferers Trading Off Youthful Skin for Treating Acne - Two Linked Conditions
More from this issue of Healthcare Mergers, Acquisitions and Ventures Week

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry